|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5440 EUR | +2.45% |
|
+6.46% | -64.58% |
| 13/07 | AB Science to Discontinue Three Masitinib-related Clinical Studies | MT |
| 11/07 | AB Science streamlines its portfolio and refocuses on two molecules |  |
Main competitors
| P/E (Y) | Price to Book (Y) | PEG (Y) | EV / Sales (Y) | EV / EBITDA (Y) | EV / EBIT (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|
 | - | - | - | - | - | - | - | 48.92M | |
| 40.63x | 6.19x | -0.72x | 5.36x | 20.7x | 27.77x | 2.62% | 321B | |
| 24.15x | 2.02x | -16.92x | 3.3x | 11.76x | 19.4x | 1.64% | 71.5B | |
| 12.49x | 13.12x | 0.08x | 6.34x | 9.66x | 10.6x | - | 9.88B | |
| 17.15x | 1.48x | 0.83x | 2.19x | 7.48x | 8.96x | 2.6% | 8.7B | |
| 20.7x | 5.5x | 2.08x | 5.84x | 16.54x | 17.22x | -.--% | 4.25B | |
| 40.64x | 2.45x | -1.36x | 2.33x | 29.2x | 43.56x | 0.75% | 3.86B | |
| 29.83x | - | 0.19x | 5.69x | 16.27x | 26.36x | - | 3.47B | |
| 102.49x | - | -0.62x | - | - | - | -.--% | 2.65B | |
| 67.4x | - | -0.13x | - | - | - | - | 1.34B | |
| 16.47x | 0.76x | -0.72x | 1.37x | 24.66x | 48.36x | 4.04% | 1.09B | |
| -66.59x | 1.62x | 1x | - | - | - | - | 896M | |
| Average | 27.76x | 4.14x | -1.48x | 4.05x | 17.03x | 25.28x | 1.66% | 35.69B | |
| Weighted average by Cap. | 36.65x | 5.49x | -3.34x | 4.94x | 18.67x | 25.65x | 2.39% |
- Stock Market
- Stocks
- AB Stock
- Sector AB Science
- Sector valuations
Select your edition
All financial news and data tailored to specific country editions
